Journals / Medicine Science / 2019 / Cilt: 8 - Sayı: 3

Evaluation of glycemic control by metformin + glitazone + DPP-4 inhibitor + SGLT-2 inhibitor combination in patients with type 2 diabetes quitting basal/bolus insulin therapy

Pages
687–691
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The study suggested that metformin + glitazone + DPP-4 inhibitor + SGLT-2 inhibitor combination may be effective to maintain glycemic control in some type 2 diabetic patients who could not keep up insulin therapy and/or who developed clinical inertia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Type 2 diabetes mellitus is one of the most common chronic diseases worldwide and one of the highest morbidity factors.
📊
Key Findings & Data:Lowering the levels of Hemoglobin A1c (HbA1c) by strict glycemic control is the most important predictor of preventing complications.
💡
Conclusion & Impact:The study suggested that metformin + glitazone + DPP-4 inhibitor + SGLT-2 inhibitor combination may be effective to maintain glycemic control in some type 2 diabetic patients who could not keep up insulin therapy and/or who developed clinical inertia.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Type 2 diabetes mellitus is one of the most common chronic diseases worldwide and one of the highest morbidity factors. Lowering the levels of Hemoglobin A1c (HbA1c) by strict glycemic control is the most important predictor of preventing complications. Insulin, one of the long-term drugs used to achieve this goal, however adherence and persistence to insulin therapy is not so high due to some barrier such fear of injections, fear of hypoglycaemia, obesity risk etc. This study designed to retrospectively evaluate change in glycemic control of patients with type 2 diabetes who had been on insulin therapy and wanted to quit or unwilling to use insulin therapy for any reason, and given oral antidiabetic combination therapy (metformin + glitazone + DPP-4 inhibitor + SGLT-2 inhibitor). A total of 76 patients met the inclusion criteria’s were retrospectively analyzed from hospital records. HbA1c, body mass index, and fasting plasma glucose levels were evaluated while using basal/bolus insulin therapy and after oral anti diabetic combination therapy. After antidiabetic combination therapy all glycemic control parameters significantly improved. 39.5% of the patients reached the glycemic target (HbA1c< 7%), and mean HbA1c level decreased 1.9%. The study suggested that metformin + glitazone + DPP-4 inhibitor + SGLT-2 inhibitor combination may be effective to maintain glycemic control in some type 2 diabetic patients who could not keep up insulin therapy and/or who developed clinical inertia.

🔖

Cite This Article

GOZUKARA, M. Y., ORUC, I. (2019). Evaluation of glycemic control by metformin + glitazone + DPP-4 inhibitor + SGLT-2 inhibitor combination in patients with type 2 diabetes quitting basal/bolus insulin therapy. Medicine Science, Cilt: 8 - Sayı: 3, 687–691. https://ajindex.com/articles/277111

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. WHO. “Diabetes Mellitus Fact Sheets.” https://www.who.int/mediacentre/factsheets/fs138/en/ access date 22.05.2019 2. DeFronzo RA. From the triumvirate to the „ominous octet”: a new paradigm for the treat-ment of type 2 diabetes mellitus. Clin Diab. 2009;10:101-28. 3. The diabetes control and complications trial research group. The effect of intensive treat-ment of diabetes onthe development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86 4. Group UPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53. 5. Nakagami T, Kawahara R, Hori S, et al. Glycemic Control and Prevention of Retino-pathy in Japanese NIDDM Patients: A 10-year follow-up study. Diabetes Care. 1997;20:621-2. 6. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complica-tions in diabetes mellitus. Ann Intern Med. 1996;124(1_Part_2):90-6. 7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Manage-ment of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care. 2012;35:1364-79. 8. Federation I. IDF Diabetes Atlas Eighth Edition 2017/2017. 9. Satman İ, Grubu TÇ. TURDEP-II Çalışması ilk sonuçlar, 32. TEMH Kongresi. 13-17 Ekim 2010.
  2. Antalya, Türkiye. 10. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.J Clin Endocrinol. 2013;98:1845-59. 11. TEMD Diabetes Mellitus ve Komplikasyonlarının Tanı, Tedavi ve İzlem Kılavuzu-2018. http://www.temd.org.tr/admin/uploads/tbl_gruplar/2018051711 926-2018-05-17tbl_gruplar113924.pdf acces date:22.05.2019 12. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-9. 13. DeFronzo RA, Goodman AM, Group MMS. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-9. 14. Knowler WC, Barrett-Connor E, Fowler SE, et al. Re-duction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. 15. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-18. 16. Kahn SE, Haffner SM, Heise MA, et al. Glycemic du-rability of rosiglitazone, metformin, or glyburide monotherapy. N Eng